GNH USA

Europe — EMA

Idefirix (Imlifidase)

GNH USA supplies Idefirix (Imlifidase), an IgG‑degrading enzyme for desensitization in HLA‑incompatible kidney transplants. Request a quote for global supply.

Imlifidase

Request sourcing

1
Pack/s

What is Imlifidase?

Imlifidase, the active ingredient in Idefirix, is an IgG‑degrading enzyme (IdeS) presented as an intravenous solution for infusion use. It is employed to rapidly reduce donor‑specific antibodies in patients undergoing HLA‑incompatible kidney transplantation, facilitating successful graft acceptance. Its rapid IgG cleavage enables a transient immunosuppressive window, allowing clinicians to proceed with transplantation without prolonged desensitization protocols.

GNH USA supplies Idefirix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and transplant centres worldwide. The company adheres to stringent quality standards and provides cold‑chain logistics where required to maintain product integrity.

What is Imlifidase used for?

Idefirix is used in the field of transplant immunology to manage antibody‑mediated barriers to kidney transplantation.

HLA‑incompatible kidney transplantation: enables transplantation by rapidly reducing donor‑specific antibodies. Sensitized renal transplant candidates: facilitates graft acceptance when conventional desensitization fails. Pre‑transplant antibody reduction: provides rapid IgG depletion to allow timely organ allocation.

What are the side effects of Imlifidase?

Idefirix may be associated with a range of adverse reactions following intravenous administration.

Common Side Effects: - Infusion‑related reactions such as flushing, chills, or fever. - Headache or mild dizziness. - Nausea or vomiting. - Transient hypotension during infusion.

Serious or Rare Side Effects: - Anaphylaxis or severe allergic reaction. - Serum sickness‑like manifestations. - Opportunistic infections due to temporary immunosuppression.

What precautions apply to Imlifidase?

Prior to initiating Idefirix therapy, clinicians should consider several precautionary measures.

Pregnancy: safety not established; use only if potential benefit justifies the risk. Breastfeeding: unknown excretion; weigh maternal benefit against infant risk. Infection risk: monitor for opportunistic infections during the transient immunosuppressive period. Renal function: no dose adjustment required, but graft function should be closely observed. Concomitant immunosuppressants: adjust other agents as clinically indicated. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Imlifidase interact with?

Idefirix can interact with other therapies, requiring careful management.

Major Interactions (Avoid): - Live vaccines: contraindicated during treatment and up to three months after. - Complement inhibitors: may increase risk of severe infections. - High‑dose IVIG: can neutralize Imlifidase activity.

Moderate Interactions (Monitor Closely): - Anticoagulants: monitor coagulation parameters due to possible infusion‑related reactions. - Corticosteroids: may mask infusion reactions; adjust monitoring accordingly. - Other monoclonal antibodies: assess for additive immunosuppression.

Frequently asked questions

What is Idefirix used for?+
Idefirix is indicated for desensitization in patients who are HLA‑incompatible for kidney transplantation. By rapidly degrading circulating IgG antibodies, it reduces donor‑specific antibodies, creating a window that allows the transplant to proceed safely.
How does Imlifidase work?+
Imlifidase is an IgG‑degrading enzyme that cleaves human IgG at the lower hinge region, separating the molecule into F(ab')2 and Fc fragments. This action swiftly eliminates donor‑specific antibodies, lowering immunologic risk and facilitating transplantation.
What is the usual dose of Idefirix?+
The dosing regimen for Idefirix is determined by the treating physician based on the patient’s clinical status, antibody levels, and transplant protocol. No fixed public dosing schedule is provided; the prescriber sets the appropriate dose.
Is Idefirix safe in pregnancy or breastfeeding?+
Safety data for Idefirix in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and decisions should be made in consultation with a specialist.
How do I order Idefirix from GNH USA?+
To order Idefirix, submit an enquiry on the product page at gnh-usa.com specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling), and necessary import documentation.
How does Idefirix compare with the main alternative drug or class?+
The primary alternatives for antibody‑mediated desensitization include plasmapheresis, intravenous immunoglobulin (IVIG), and rituximab. Idefirix offers a rapid, single‑dose reduction of IgG antibodies, whereas the alternatives often require multiple sessions over several weeks and may have broader immunosuppressive effects.
What are the storage and handling requirements for Idefirix?+
Idefirix must be stored refrigerated at 2‑8 °C. It should be kept in its original container, protected from light, and must not be frozen or shaken. Maintaining the cold chain during transport is essential to preserve product potency.
How is Idefirix administered?+
Idefirix is administered as an intravenous infusion under the supervision of a transplant specialist. The infusion is typically given over a short period, with vital signs monitored before, during, and after the procedure to detect any infusion‑related reactions.
What are the most serious risks to watch for with Idefirix?+
Serious risks include anaphylaxis, serum‑sickness‑like reactions, and opportunistic infections due to the temporary loss of IgG‑mediated immunity. Patients should be observed closely during infusion and monitored for signs of severe allergic response or infection in the days following treatment.
Who should not use Idefirix?+
Idefirix is contraindicated in patients with known hypersensitivity to Imlifidase or any component of the formulation, and in individuals who have received live vaccines within four weeks prior to treatment. Caution is also advised for patients with uncontrolled infections or severe uncontrolled comorbidities.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Imlifidase
Route
Intravenous Use
Manufacturer
Hansa Biopharma Ab
Origin
EU

Related products

Idefirix

Idefirix

Imlifidase

Hansa Biopharma Ab
EU
Idefirix

Idefirix

Imlifidase

Hansa Biopharma Ab
EU
Idefirix

Idefirix

Imlifidase

Hansa Biopharma Ab
EU